What the science actually says - and doesn't
The ten pounds no study has ever tested
A woman I train is 47.
Her relationship with food and exercise over the years has been what it is for a lot of people: on, then off, then on again. A good year, then a rough one. Kids. A move. A job that ate her evenings for eighteen months.
She’s never been a machine about it. She’s been a busy adult who cares about her health and sometimes has the bandwidth for it and sometimes doesn’t.
Then, somewhere in perimenopause, ten pounds arrived.
Nothing on a checkup suggests anything is wrong with her. She isn’t obese. She doesn’t have diabetes. She’s active. But those ten pounds haven’t responded the way weight used to when she got serious about it.
A few months ago she stood in a dressing room, looked at herself in a pair of jeans that used to fit, and texted me a photo with one line:
“Is this just what 47 looks like now?”
Then she asked the real question.
Should she start taking Ozempic?
She’s not the only one asking. Some version of this question now comes up regularly with clients, and increasingly it isn’t coming from people with obesity. It’s coming from healthy people who would simply like to be ten pounds lighter.
And that’s where the evidence gets surprisingly murky.
Before I go any further, I want to be clear about something: this isn’t an argument against GLP-1 drugs.
For people living with obesity, type 2 diabetes, or significant metabolic risk, these medications have changed what is possible. The evidence for their use in those populations is substantial, and the benefits can extend far beyond fitting into smaller clothes. For the right person, taking one long term may make complete sense.
That’s not the person I’m writing about.
I’m interested in the much newer group showing up in these conversations: people who are already reasonably healthy, aren’t obese, don’t have diabetes, and want to use a very lowdose to lose the last ten or fifteen pounds.
That’s a completely different risk-benefit calculation.
And it’s one science hasn’t really tested.
The person nobody studied
We already know these drugs work extraordinarily well for obesity.
In the major semaglutide trials, people lost around 15 percent of their body weight. But when researchers followed participants after they stopped taking the medication, they found that within a year they’d regained roughly two-thirds of what they’d lost.
That statistic gets repeated constantly, usually as proof that Ozempic “doesn’t work.”
I don’t think that’s what it proves.
If someone loses 50 pounds and ultimately keeps 15 or 20 of those pounds off, they may quite reasonably consider the treatment successful.
And newer research makes the picture less tidy. Some real-world data suggest many people retain at least some of their weight loss two years after stopping. Other analyses project that average weight could return close to baseline within roughly a year and a half.
So we don’t yet know exactly where everyone eventually lands.
What we do know is that stopping the medication commonly means regaining weight.
For many people taking GLP-1 drugs, that isn’t particularly surprising. These medications are increasingly treated as long-term therapy, much like medication for other chronic conditions. Stop the medication and the biological effect you’re treating doesn’t necessarily disappear with it.
For someone with obesity or significant metabolic disease, that may be a completely reasonable trade. If a medication substantially improves your health and quality of life, the fact that you may need to keep taking it isn’t necessarily an argument against it.
But my client isn’t that person.
She’s healthy.
She wants to lose ten pounds.
So the question isn’t really whether she’d be willing to stay on the medication.
It’s this:
Is losing ten pounds for aesthetic reasons worth potentially taking a medication for the next twenty or thirty years when we can’t yet know what twenty or thirty years of use looks like in someone like her?
Maybe it is.
But that’s a very different calculation from treating obesity or diabetes.
Then came microdosing
“Microdosing” sounds reassuringly precise, but it isn’t actually a standardized medical protocol.
It can mean staying on the introductory dose, taking less than that, spacing injections farther apart, or simply taking the smallest amount that quiets appetite enough to make eating less easier.
And here’s the important part:
We have remarkably little good long-term research on this use in healthy, normal-weight people.
That’s less surprising once you look at the timeline. Ozempic was approved for diabetes in 2017. The weight-loss version, Wegovy, wasn’t approved until 2021. Mainstream, cosmetic, “everyone I know is on it” use didn’t really take off until 2022 and 2023. This entire conversation is maybe five years old, and the specific question of a healthy person microdosing for a decade or two hasn’t had time to be asked, let alone answered.
That doesn’t mean microdosing is dangerous.
It also doesn’t mean it’s safe for twenty years.
It means the practice has moved faster than the research.
The known side effects aren’t mysterious. Nausea, constipation, diarrhea, vomiting and other gastrointestinal problems are common, and less-common complications such as gallbladder problems and pancreatitis can occur.
For someone with obesity or diabetes, accepting those risks in exchange for substantial health benefits may be an easy calculation.
For someone taking a tiny dose because she wants her old jeans to fit?
Again, different calculation.
And I don’t think there’s anything wrong with admitting that the goal is aesthetic.
We make aesthetic decisions about our bodies all the time.
The question isn’t whether wanting to look different is legitimate.
The question is what you’re willing to trade for it.
What about muscle?
This was one of my biggest concerns when I first started looking into GLP-1 drugs.
And it’s an area where the science has become a bit more reassuring.
Dr. Stacy Sims is an exercise physiologist and researcher whose work focuses heavily on female physiology, particularly how women should train and fuel through midlife and menopause. She has been outspoken about protecting muscle, strength and bone as women age, and she’s particularly skeptical about already healthy women using GLP-1 drugs to chase a few “vanity pounds.”
Her concern makes sense.
Muscle and bone become more important as we age, not less. If becoming ten pounds lighter means becoming weaker and sacrificing valuable lean tissue, that’s a terrible trade.
Dr. Peter Attia, a physician whose work focuses on longevity and preventing chronic disease, raised similar concerns in 2023.
Early body-composition studies seemed to suggest people taking GLP-1 drugs were losing alarming amounts of lean mass along with fat.
Then better evidence came along.
And Attia changed his position.
Part of the problem was measurement. “Lean mass” on a scan isn’t synonymous with muscle. It also includes water and other fat-free tissue. More recent research has found people losing some measured lean mass while maintaining or even improving strength and muscle quality.
Attia revisited his earlier concerns publicly in 2026.
That matters.
The concern wasn’t imaginary. Substantial weight loss usually does take some lean tissue with it, regardless of how the weight comes off.
But the early panic that Ozempic somehow uniquely destroys enormous quantities of functional muscle appears to have been overstated.
The better question is:
What are you doing while you lose weight to give your body every reason to keep the muscle you have?
And that’s where this becomes about much more than a weekly injection.
The drug doesn’t build the person underneath it
James Clear, author of Atomic Habits, writes about the difference between pursuing an outcome and building an identity.
Losing ten pounds is an outcome.
Becoming someone who trains three times a week is an identity.
Fitting into your old jeans is an outcome.
Becoming someone who eats enough protein, protects her sleep and keeps moving when life gets messy is an identity.
A GLP-1 can make the outcome dramatically easier.
It can suppress appetite. It can quiet the constant thoughts about food that many people describe as “food noise.”
For someone who has lived with that noise for years, turning it off can feel extraordinary.
Another client of mine started a low dose last year and described it simply:
“The noise just stopped.”
For the first time in years, she wasn’t thinking about food between meals. She could eat and then simply move on with her day.
That’s not nothing.
And it’s one reason I find some of the moralizing around these drugs irritating.
Appetite isn’t a character flaw.
But the medication doesn’t automatically build anything underneath the weight loss.
It doesn’t make you stronger.
It doesn’t put protein on your plate.
It doesn’t create a training habit.
It doesn’t protect your sleep.
It doesn’t teach you what to do when work gets crazy again.
And habits aren’t magic. They won’t necessarily overpower the biological increase in appetite that can happen when the medication is stopped.
But they’re still the foundation you want underneath whatever happens next.
A drug can remove an obstacle. It can’t build the entire house.
Sometimes effort really is part of it
There’s another side of this conversation that’s uncomfortable to talk about because we’ve become rightly cautious about blaming people for their weight.
But sometimes behaviour really is part of the problem.
Some people asking about GLP-1s aren’t exercising consistently. They aren’t eating enough protein. They’re sleeping five hours a night. Stress is running the show. They’ve never maintained a sensible calorie deficit for more than a week or two.
They’re asking whether medication can solve a problem before they’ve genuinely tried the fundamentals.
That’s real. It’s also, not coincidentally, most of what we spend our time on at Beyond Fitness — not because it’s glamorous, but because it’s the part that holds up once nothing else is propping the result up.
But my 47-year-old client isn’t quite that person.
She’s tried.
Not perfectly. Not continuously. But for years, in the way real people do.
What worked at 35 simply seems considerably harder at 47.
Telling her to “try harder” isn’t particularly useful.
Neither is pretending that taking a weekly injection solves the entire problem.
If you decide to use it
This is probably where I’ve landed after spending countless hours digging deeply into GLP-1's, reading the research and meta-analyses, and listening to experts with very different perspectives on these drugs.
If you’re healthy and considering a low dose to lose five or ten pounds, I can’t tell you that research proves it’s a bad idea.
It doesn’t.
I also can’t tell you that research proves it’s harmless over decades.
It doesn’t do that either.
But if you decide the trade makes sense for you, there are a few things I’d protect far more fiercely than the number on the scale:
Strength train consistently. Give your body a reason to preserve muscle while weight is coming off.
Prioritize protein. Appetite suppression makes it surprisingly easy to under-eat everything, including what your muscles need.
Lose slowly. If the goal is ten pounds, there’s no prize for doing it in six weeks.
Watch performance as well as weight. Ten pounds lighter but substantially weaker isn’t necessarily progress.
If you’re perimenopausal or beyond, get a baseline read on bone density and check it periodically. This is the one area where the incomplete evidence still gives Sims’s caution the most weight.
Plan your exit before you need it. Titrate down slowly instead of stopping cold, and treat coming off the drug as its own phase, not an afterthought.
Think about the long game before you start. This may not be a medication you take for three months and forget about.
And most importantly:
Build the habits you’d want to have if the prescription disappeared tomorrow.
Not because good habits guarantee you’ll never regain weight.
Because they’re worth having regardless.
So, should she take it?
I still don’t know.
And I think that’s the most truthful answer.
If she had obesity, type 2 diabetes or significant metabolic disease, we’d have an enormous body of research to help answer the question.
But she doesn’t.
She’s 47, healthy, active and wants to lose ten stubborn pounds.
That woman hasn’t really been studied.
Maybe low-dose GLP-1 use will eventually turn out to be an extremely effective, relatively low-risk way for people like her to manage body composition through midlife.
Maybe we’ll discover that taking a powerful appetite-regulating medication for decades to maintain an aesthetic preference was a trade that didn’t any sense.
We need time to know.
A few months after that dressing-room photo, my client texted me again.
Not about Ozempic.
She’d finished a workout before work. She was tired, pleased with herself and wanted me to know she’d done it.
The ten pounds still hadn’t moved.
She’s still deciding what to do about the number.
But she’s already building something underneath it.
And whether she eventually takes the injection or doesn’t, that part was never going to be optional.
If you’re having the same conversation with yourself, start there. Ask what you’re actually trying to solve, what you’ve already tried, and what you’re willing to build alongside the medication if you use it.
The drug may end up being part of the answer.
It was never going to be the whole one.
1551-211 Cedar Hill X Rd 250-891-9363
Comments